Keystone Malaria Symposium 2022: a Vibrant Discussion of Progress Made and Challenges Ahead from Drug Discovery to Treatment

Overview

Journal Trends Parasitol

Specialty Parasitology

Date 2022 Jul 21

PMID 35864072

Authors

Mariko Kanai

Laura M Hagenah

Elizabeth A Ashley

Kelly Chibale

David A Fidock

Affiliations

Soon will be listed here.

Citing Articles

Defining the next generation of severe malaria treatment: a target product profile.

Achan J, Barry A, Leroy D, Kamara G, Duparc S, Kaszubska W Malar J. 2024; 23(1):174.

PMID: 38835069 PMC: 11151482. DOI: 10.1186/s12936-024-04986-z.

References

Arendse L, Wyllie S, Chibale K, Gilbert I . Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities. ACS Infect Dis. 2021; 7(3):518-534. PMC: 7961706. DOI: 10.1021/acsinfecdis.0c00724. View

Duffey M, Blasco B, Burrows J, Wells T, Fidock D, Leroy D . Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials. Trends Parasitol. 2021; 37(8):709-721. PMC: 8282644. DOI: 10.1016/j.pt.2021.04.006. View

Summers R, Pasaje C, Pisco J, Striepen J, Luth M, Kumpornsin K . Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. Cell Chem Biol. 2021; 29(2):191-201.e8. PMC: 8878317. DOI: 10.1016/j.chembiol.2021.07.010. View

Murithi J, Pascal C, Bath J, Boulenc X, Gnadig N, Pasaje C . The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to parasite resistance. Sci Transl Med. 2021; 13(603). PMC: 8530196. DOI: 10.1126/scitranslmed.abg6013. View

Vanachayangkul P, Im-Erbsin R, Tungtaeng A, Kodchakorn C, Roth A, Adams J . Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in Rhesus Macaques. Antimicrob Agents Chemother. 2020; 64(9). PMC: 7449176. DOI: 10.1128/AAC.00741-20. View

Maher S, Vantaux A, Cooper C, Chasen N, Cheng W, Joyner C . A Phenotypic Screen for the Liver Stages of . Bio Protoc. 2022; 11(23):e4253. PMC: 8678555. DOI: 10.21769/BioProtoc.4253. View

Taylor W, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A . Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019; 394(10202):929-938. PMC: 6753019. DOI: 10.1016/S0140-6736(19)31285-1. View

Mahindra A, Janha O, Mapesa K, Sanchez-Azqueta A, Alam M, Amambua-Ngwa A . Development of Potent CLK3 Inhibitors Based on TCMDC-135051 as a New Class of Antimalarials. J Med Chem. 2020; 63(17):9300-9315. PMC: 7497403. DOI: 10.1021/acs.jmedchem.0c00451. View

Button-Simons K, Kumar S, Carmago N, Haile M, Jett C, Checkley L . The power and promise of genetic mapping from Plasmodium falciparum crosses utilizing human liver-chimeric mice. Commun Biol. 2021; 4(1):734. PMC: 8203791. DOI: 10.1038/s42003-021-02210-1. View

10.

van der Pluijm R, Tripura R, Hoglund R, Phyo A, Lek D, Ul Islam A . Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet. 2020; 395(10233):1345-1360. PMC: 8204272. DOI: 10.1016/S0140-6736(20)30552-3. View

11.

Corpas-Lopez V, Wyllie S . Utilizing thermal proteome profiling to identify the molecular targets of anti-leishmanial compounds. STAR Protoc. 2021; 2(3):100704. PMC: 8384900. DOI: 10.1016/j.xpro.2021.100704. View

12.

Fofana B, Takala-Harrison S, Ouattara A, Sagara I, Togo A, Diakite H . Differential Incidence of Malaria in Neighboring Villages in a High-Transmission Setting of Southern Mali. Am J Trop Med Hyg. 2022; 106(4):1209-1214. PMC: 8991365. DOI: 10.4269/ajtmh.21-0788. View

13.

Peto T, Tripura R, Callery J, Lek D, Nghia H, Nguon C . Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infect Dis. 2022; 22(6):867-878. PMC: 9132777. DOI: 10.1016/S1473-3099(21)00692-7. View

14.

Xie S, Metcalfe R, Dunn E, Morton C, Huang S, Puhalovich T . Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy. Science. 2022; 376(6597):1074-1079. PMC: 7613620. DOI: 10.1126/science.abn0611. View

15.

Taft B, Yokokawa F, Kirrane T, Mata A, Huang R, Blaquiere N . Discovery and Preclinical Pharmacology of INE963, a Potent and Fast-Acting Blood-Stage Antimalarial with a High Barrier to Resistance and Potential for Single-Dose Cures in Uncomplicated Malaria. J Med Chem. 2022; 65(5):3798-3813. PMC: 9278664. DOI: 10.1021/acs.jmedchem.1c01995. View

16.

Nasamu A, Falla A, Pasaje C, Wall B, Wagner J, Ganesan S . An integrated platform for genome engineering and gene expression perturbation in Plasmodium falciparum. Sci Rep. 2021; 11(1):342. PMC: 7801740. DOI: 10.1038/s41598-020-77644-4. View

17.

Stokes B, Dhingra S, Rubiano K, Mok S, Straimer J, Gnadig N . K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. Elife. 2021; 10. PMC: 8321553. DOI: 10.7554/eLife.66277. View

18.

Andrews K, Owen J, McCarthy J, Wesche D, Gobeau N, Grasela T . Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development. Clin Transl Sci. 2020; 14(2):712-719. PMC: 7993277. DOI: 10.1111/cts.12934. View

19.

Yang T, Ottilie S, Istvan E, Godinez-Macias K, Lukens A, Baragana B . MalDA, Accelerating Malaria Drug Discovery. Trends Parasitol. 2021; 37(6):493-507. PMC: 8261838. DOI: 10.1016/j.pt.2021.01.009. View

20.

Uwimana A, Legrand E, Stokes B, Ndikumana J, Warsame M, Umulisa N . Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020; 26(10):1602-1608. PMC: 7541349. DOI: 10.1038/s41591-020-1005-2. View